EUVIMEDOpdag EUVIMED
Crossref

Silibinin attenuated pseudo‐allergic reactions and mast cell degranulation via PLCγ and PI3K /Akt signaling pathway

Yuejin Wang iD, Shiting Hu, Baowen Dang, Yonghui Zhang, Guodong Zheng, Chenrui Zhao, Yihan Huang, Tao Zhang

Phytotherapy Research · 2023

DOI: 10.1002/ptr.7835 ↗

At a glance

Journal article in Phytotherapy Research, 2023. Written by Yuejin Wang and 7 co-authors. Institution: Xi'an Jiaotong University School of Medicine, Xi'an, China. Major MEDLINE topics: Anaphylaxis, Anti-Allergic Agents. Cited 3 times so far (Crossref); 28 references. Funded by: Institutional Science Foundation of The First Affiliated Hospital of Xi'an Jiaotong University, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Anaphylaxis is a type of potentially fatal hypersensitivity reaction resulting from the activation of mast cells. Many endogenous or exogenous factors could cause this reaction. Silibinin is the main chemical component of silymarin and has been reported to have pharmacological activities. However, the anti‐allergic reaction effect of silibinin has not yet been investigated. This study aimed to evaluate the effect of silibinin to attenuate pseudo‐allergic reactions in vivo and to investigate the underlying mechanism in vitro. In this study, calcium imaging was used to assess Ca 2+ mobilization. The levels of cytokines and chemokines, released by stimulated mast cells, were measured using enzyme immunoassay kits. The activity of silibinin was evaluated in a mouse model of passive cutaneous anaphylaxis (PCA). Western blotting was used to explore the related molecular signaling pathways. In results, silibinin markedly inhibited mast cell degranulation, calcium mobilization, and preventing the release of cytokines and chemokines in a dose‐dependent manner via the PLCγ and PI3K/Akt signaling pathway. Silibinin also attenuated PCA in a dose‐dependent manner. In summary, silibinin has an anti‐pseudo‐allergic pharmacological activity, which makes it a potential candidate for the development of a novel agent to arrest pseudo‐allergic reactions.

Subjects

MeSH terms (MEDLINE)

AnaphylaxisAnti-Allergic AgentsMiceAnimalsSilybinProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCell DegranulationMast CellsCalciumSignal TransductionCytokinesChemokines

Author keywords

PI3K/Aktmast cellpseudo-allergysilibinin

Substances

SilybinProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCalciumCytokinesChemokinesAnti-Allergic Agents

Authors and institutions

  • Xi'an Jiaotong University School of Medicine, Xi'an, China.

ORCID profiles: Yuejin Wang

Funding

  • Institutional Science Foundation of The First Affiliated Hospital of Xi'an Jiaotong University
  • National Natural Science Foundation of China

Cite

APA

Wang, Y., Hu, S., Dang, B., Zhang, Y., Zheng, G., Zhao, C., Huang, Y., & Zhang, T. (2023). Silibinin attenuated pseudo‐allergic reactions and mast cell degranulation via PLCγ and PI3K /Akt signaling pathway. Phytotherapy Research. https://doi.org/10.1002/ptr.7835

Vancouver

Wang Y, Hu S, Dang B, Zhang Y, Zheng G, Zhao C, et al. Silibinin attenuated pseudo‐allergic reactions and mast cell degranulation via PLCγ and PI3K /Akt signaling pathway. Phytotherapy Research. 2023. doi:10.1002/ptr.7835

BibTeX
@article{Wang2023,
  author = {Wang, Yuejin and Hu, Shiting and Dang, Baowen and Zhang, Yonghui and Zheng, Guodong and Zhao, Chenrui and Huang, Yihan and Zhang, Tao},
  title = {Silibinin attenuated pseudo‐allergic reactions and mast cell degranulation via PLCγ and PI3K /Akt signaling pathway},
  journal = {Phytotherapy Research},
  year = {2023},
  doi = {10.1002/ptr.7835}
}
Start for free →